Arvaya Healthcare holds 41st AGM, approves IP acquisition and rights issue

scanx
Reviewed by
Naman SScanX News Team
Key Highlights
  • Shareholders approved adoption of FY26 audited financial statements
  • Material related-party transaction for IP acquisition from DEFIB Institute approved
  • Rights issue authorized to fund expansion and subsidiary operations
  • Company rebranded to Arvaya Healthcare Limited during the meeting
powered bylight_fuzz_icon
51554637

*this image is generated using AI for illustrative purposes only.

Arvaya Healthcare Limited concluded its 41st Annual General Meeting on September 21, 2026, where shareholders approved a material related-party transaction for intellectual property acquisition and authorized a rights issue to fund expansion.

The meeting, held via video conferencing in compliance with Ministry of Corporate Affairs and SEBI circulars, commenced at 3:02 pm and ended at 3:31 pm. Kaushal Uttam Shah, Managing Director, presided over the proceedings.

Key Resolutions

Shareholders transacted the following items of business:

  • Adoption of audited standalone and consolidated financial statements for the fiscal year ended March 31, 2026.
  • Re-appointment of Kaushal Uttam Shah as Managing Director, who retires by rotation.
  • Approval of material related-party transactions under Section 188 of the Companies Act, 2013, and Regulation 23 of SEBI Listing Regulations.
  • Approval for the acquisition and assignment of the copyright and intellectual property portfolio of DEFIB Institute of Health Solutions LLP using proceeds from the rights issue.

Strategic Updates

The Chairman highlighted several strategic developments during the meeting:

  • Re-branding: The company officially transitioned to Arvaya Healthcare Limited to reflect its expanded focus in the healthcare sector.
  • Subsidiary Incorporation: Arvaya Insurance Broking Private Limited was incorporated as a wholly owned subsidiary on September 17, 2026, to diversify operations.
  • Acquisition Process: The company is currently acquiring Sushoda Institute of Gastroenterology Private Limited to expand its healthcare footprint.
  • Capital Raising: A rights issue of equity shares is underway to support these growth initiatives and strengthen balance sheet capacity.

CS Guinea Agrawal served as the convener, while Mr. Chinmay Mohan Lele was appointed as the scrutinizer for the e-voting process. Remote e-voting ran from September 18 to September 20, 2026.

Historical Stock Returns for Arvaya Healthcare

1 Day5 Days1 Month6 Months1 Year5 Years
+4.96%-0.25%+12.69%0.0%+314.93%0.0%

How will the proceeds from the rights issue specifically impact Arvaya Healthcare's debt-to-equity ratio and overall liquidity position?

What is the expected timeline for integrating the intellectual property from DEFIB Institute into Arvaya's core product offerings?

How does the newly incorporated Arvaya Insurance Broking subsidiary plan to cross-sell services with the existing healthcare operations?

Arvaya Healthcare AGM to approve ₹390 crore related party transactions

scanx
Reviewed by
Suketu GScanX News Team
Key Highlights
  • Arvaya Healthcare AGM scheduled for September 21, 2026, via video conference
  • Shareholders to approve ₹390 crore in related party transactions for FY27
  • Reappointment of Managing Director Kaushal Uttam Shah on agenda
  • E-voting period set for September 18-20, 2026
powered bylight_fuzz_icon
49360165

*this image is generated using AI for illustrative purposes only.

Arvaya Healthcare Limited (formerly Bijoy Hans Limited) will hold its 41st Annual General Meeting on Monday, September 21, 2026, at 3:00 pm via video conference. The meeting aims to approve the reappointment of Managing Director Kaushal Uttam Shah and sanction material related party transactions totaling ₹390 crore for FY27.

The company published the notice of the AGM and the Annual Report for the financial year 2025-26 in compliance with Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. The advertisement appeared in Financial Express (All India English edition) and Dainadin Barta (Guwahati Assamese edition) on August 27, 2026. A subsequent communication dated August 28, 2026, confirmed the notice details to BSE Limited.

Meeting Details

Shareholders can access the notice of the AGM and the annual report on the company’s website. The copies of the newspaper advertisements are also available online.

Members holding shares in physical form who have not registered their email IDs are requested to update them with the Registrar to an Issue and Share Transfer Agent, Maheshwari Databotics Private Limited. Members holding dematerialized shares should register or update their email IDs with their respective Depository Participants.

Voting Process

The company will provide a remote e-voting facility to all members to cast votes on the resolutions set forth in the notice. Additionally, voting through an e-voting system during the AGM will be available. Detailed procedures for remote e-voting and voting at the AGM are provided in the notice.

Key dates for the voting process are as follows:

Particulars Date
Cut-off date for dispatch of notice August 21, 2026
Cut-off date for E-voting September 14, 2026
E-voting period September 18, 2026 to September 20, 2026

Pursuant to applicable SEBI circulars, a special window for the transfer and dematerialization of physical securities sold or purchased prior to April 1, 2019, remains open from February 5, 2026, to February 4, 2027. Securities transferred under this window must be credited in dematerialized form.

Key Resolutions

The AGM agenda includes ordinary business items such as the adoption of audited standalone and consolidated financial statements for FY26. Key special business resolutions include:

  • Reappointment of Managing Director: Reappointment of Mr. Kaushal Uttam Shah (DIN: 02175130), who retires by rotation.
  • Material Related Party Transactions (RPTs): Approval for entering into material related party transactions with promoters, promoter group companies, and wholly owned subsidiaries for FY27. The aggregate value of proposed transactions is ₹390 crore.
  • IP Acquisition: Approval for the acquisition of the Copyright and Intellectual Property portfolio of DEFIB Institute of Health Solutions LLP for up to ₹10 crore, funded from Rights Issue proceeds.

Related Party Transactions

The company seeks shareholder approval for material related party transactions under Section 188 of the Companies Act, 2013, and Regulation 23 of SEBI Listing Regulations. The proposed transactions involve loans, advances, and services with various related parties.

Related Party Relationship Proposed Transaction Value (₹ Crore)
Agri One India Ventures LLP Promoter 40
UG Patwardhan Services Private Limited Promoter 40
Kaushal Uttam Shah Promoter / MD 40
GTT Data Solutions Limited Promoter Group 40
SMCV Management Services Private Limited Promoter Group 50
Tec-Pool Solutions Private Limited Wholly Owned Subsidiary 40
Health Secure Hospitals Private Limited Wholly Owned Subsidiary 40
Arvaya Healthtech & Wellness Private Limited Wholly Owned Subsidiary 40
Sushodha Institute of Gastroenterology Private Limited Related Party 40

These transactions are expected to be conducted at arm's length and in the ordinary course of business. The approval will remain valid until the next AGM.

DEFIB IP Acquisition

The company proposes to acquire the identified Copyright and Intellectual Property portfolio of DEFIB Institute of Health Solutions LLP, including patient relationship and ambulance management software. The consideration will not exceed ₹10 crore, determined based on an independent valuation. This transaction constitutes a material related party transaction as Executive Director Bidari Kotresh Anilkumar is a Designated Partner of DEFIB. The acquisition is funded from the proceeds of the company's Rights Issue.

Historical Stock Returns for Arvaya Healthcare

1 Day5 Days1 Month6 Months1 Year5 Years
+4.96%-0.25%+12.69%0.0%+314.93%0.0%

How might the approval of ₹390 crore in related party transactions impact minority shareholder confidence and the company's stock valuation in FY27?

What specific synergies or revenue growth projections does Arvaya Healthcare expect from acquiring DEFIB Institute's IP portfolio for up to ₹10 crore?

Given that the DEFIB acquisition is funded by Rights Issue proceeds, how will this capital deployment affect the company's cash flow and debt levels in the near term?

More News on Arvaya Healthcare

1 Year Returns:+314.93%